(Q46726992)

English

A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

0 references

A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

0 references

0 references

author name string

G I Papakostas

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

C H Homberger

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

M Fava

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

language of work or name

0 references

publication date

28 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

22

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

843-848

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

A Review of the Pharmacological and Clinical Profile of Mirtazapine

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

The pharmacology of putative early-onset antidepressant strategies

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Definition and epidemiology of treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Understanding research synthesis (meta-analysis).

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

The apolipoprotein E ε4 allele and antidepressant efficacy in cognitively intact elderly depressed patients

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Pharmacogenetics of antidepressant medication intolerance

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Empirical testing of two models for staging antidepressant treatment resistance.

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

A comparison of fluvoxamine and fluoxetine in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083808

21 January 2018

Identifiers

10.1177/0269881107083808

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18308801

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46726992&oldid=2128482980"